Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

World Journal of Urology

Volumn 23, Issue 1, 2005, Pages 38-46

  Gleave, Martin ^a   Miyake, Hideaki ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Clusterin; Oligonucleotide; Prostate cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BUSERELIN; CISPLATIN; CLUSTERIN; DOCETAXEL; DOXORUBICIN; FLUTAMIDE; GEMCITABINE; HORMONE; LIVER ENZYME; MITOXANTRONE; OGX 011; PACLITAXEL; PHOSPHOROTHIOIC ACID DERIVATIVE; POLYNUCLEOTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CASTRATION; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CHEMOSENSITIVITY; CHILL; CLINICAL TRIAL; DRUG HALF LIFE; DRUG POTENTIATION; ENZYME DEFECT; FEVER; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HORMONE SENSITIVITY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG CANCER; MALE; NONHUMAN; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; REVIEW; TISSUE MICROARRAY; TRANSLATION INITIATION; TUMOR RECURRENCE; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANDROGENS; ANIMALS; APOPTOSIS; CELL SURVIVAL; CLUSTERIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GLYCOPROTEINS; HUMANS; MALE; MOLECULAR CHAPERONES; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS;

EID: 15944390264     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-004-0474-0     Document Type: Review

References (81)

1. Denis L, Murphy GP (1993) Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72:3888-3895
2. Oh WK, Kantoff PW (1998) Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 160:1220-1229
3. Tannock IF, De Wit R, Berry WR et al. for the TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
4. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
5. Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982) Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer. Cancer Res 42-48:2353
6. Miyake H, Tolcher A, Gleave ME (1999) Antisense Bcl-2 oligodeoxynucleotides delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. Cancer Res 59:4030-4034
7. Miyake H, Rennie P, Nelson C, Gleave ME (2000) Testosterone-repressed prostate message-2 (TRPM-2) is an antiapoptotic gene that confers resistance to androgen ablation in prostate cancer xenograft models. Cancer Res 60:170-176
8. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D (1990) Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50:2275-2282
9. Miyake H, Nelson C, Rennie P, Gleave ME (2000) Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141:2257-2265 10.1210/en.141.6.2257
10. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox ME, Yu D, Miyake H, Gleave ME (2003) Castration-induced increased in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63:3575-3584
11. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME (1997) Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between androgen receptor and AP-1c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 272:17485-17494
12. Craft N, Shostak Y, Carey M, Sawyers C (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285 10.1038/6495
13. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C (1998) Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77:855-861
14. Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL (1999) Mitogen-activated protein kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 19:5143-5154
15. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39 10.1038/nm972
16. Ettinger SL, Sobel R, Whitmore T, Akbari M, Bradley D, Gleave M, Nelson C (2004) Dysregulation of sterol response element binding proteins and downstream effectors in prostate cancer during progression to androgen-independence. Cancer Res 64:2212-2221
17. Gimenez-Bonafe, P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC (2004) Up-regulation of the transcription factor YB-1 and its correlation with P-glycoprotein expression during prostate cancer tumor progression. Prostate 59:337-349
18. Gleave ME, Tolcher A, Miyake H, Beraldi E, Goldie J (1999) Progression to androgen-independence is delayed by antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5:2891-2898
19. Paterson R, Gleave M, Jone E, Zubovits J, Goldenberg SL, Sullivan LD (1999) Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormone therapy. Mol Urol 3:277-286
20. McDonnell TJ, Troncoso P, Brisby SM, Logothetis CL, Chung LWK, Hsieh JT et al. (1992) Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944
21. Colombel M, Symmans F, Gil S, O'Toole KM, Choplin D, Benson M et al. (1993) Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400
22. Raffo AJ, Periman H, Chen MW, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445
23. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, Van Elsas A, Muller M et al. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234
24. Miyake H, Tolcher A, Gleave ME (2000) Antisense bcl-2 oligodeoxynucleotides enhance taxol chemosensitivity and synergistically delays progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. J Natl Cancer Inst 92:34-41 10.1093/jnci/92.1.34
25. Rocchi P, So A, Kojima S. Beraldi E, Fazli L, Gleave ME (2004) Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone refractory prostate cancer. Cancer Res 64:6595-6602
26. Nickerson T, Miyake H, Gleave ME, Pollak M (1999) Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Cancer Res 59:3392-3395
27. Miyake H, Pollak, Gleave ME (2000) Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60:3058-3064
28. Tenniswood M, Wang Z, Lakins J, Morrissey C, O'Sullivan J, Tang H (1998) Clusterin in the male reproductive tract. J Androl 19:508-516
29. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J (2000) Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 50:305-315
30. Rosenberg ME, Silkensen J (1995) Clusterin and the kidney. Exp Nephrol 3: 9-14
31. Steinberg J, Oyasu R, Lang S, Sintich S, Rademaker A, Lee C, Kozlowski JM, Sensibar JA (1997) Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3:1701-1711
32. Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, Sevignani C, Calabretta B, Sala A (2000) Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem 275:21055-21060 10.1074/jbc.M002055200
33. Kyprianou N, English HF, Davidson NE, Isaacs JT (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51:162-166
34. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK (2000) Overexpression of clusterin in human breast carcinoma. Am J Pathol 157:393-399
35. Wellmann A, Thieblemont C, Pittaluga S, Sakai A, Jaffe ES, Siebert P, Raffeld M (2000) Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96:398-404
36. Parczyk K, Pilarsky C, Rachel U, Koch-Brandt C (1994) Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas. J Cancer Res Clin Oncol 120:186-188
37. Montpetit ML, Lawless KR, Tenniswood M (1986) Androgen-repressed messages in the rat ventral prostate Prostate 8: 25-36
38. Budendorf L. Kolmer M. Kononen J. et al. 1999 Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue arrays J Natl Cancer Inst 91:1758-1764 10.1093/jnci/91.20.1758
39. Kyprianou N, English HF, Isaacs JT (1990) Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753
40. Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wong P, Welsh JE (1992) Active cell death in hormone-dependent tissues. Cancer Metastasis Rev 11:197-220 10.1007/BF00048064
41. Danik M, Chabot JG, Mercier C, Benabid AL, Chauvin C, Quirion R, Suh M (1991) Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci U S A 88:8577-8581
42. Connor J, Buttyan R, Olsson CA, DAgati V, O'Toole K, Sawczuk IS (1991) SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis. Kidney Int 39:1098-1103
43. Ho SM, Leav I, Ghatak S, Merk F, Jagannathan VS, Mallery K (1998) Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am J Pathol 153:131-139
44. Schwochau GB, Nath KA, Rosenberg ME (1998) Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 53:1647-1653 10.1046/j.1523-1755.1998.00902.x
45. French LE, Sappino AP, Tschopp J, Schifferli JA (1992) Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus. J Clin Invest 90:1919-1925
46. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, Boothman DA (2000) Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci U S A 97:5907-5912
47. Koch-Brandt C, Morgans C (1996) Clusterin: A role in cell survival in the face of apoptosis? Prog Mol Subcell Biol 16:130-149
48. Michel D, Chatelain G, North S, Brun G (1997) Stress-induced transcription of the clusterin/apoJ gene. Biochem J 328:45-50 1:CAS:528:DyaK2sXotVWnur4%3D
49. Miyake H, Rennie P, Nelson C, Gleave ME (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2 (TRPM-2), in prostate cancer xenograft models. Cancer Res 60:2547-2554
50. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave M (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin Clin Cancer Res 8 3276-3284
51. Criswell T, Klokov D, Beman M, Lavik JP, Boothman DA (2003) Repression of IR-inducible clusterin expression by the p53 tumour suppression protein. Cancer Biol Ther 2:372-380
52. Crescioli C, Ferruzzi P, Caporali A, Scaltriti M, Bettuzzi S, Mancina R, Gelmini S, Serio M, Villari D, Vannelli GB, Colli E, Adorini L, Maggi M (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150: 591-603
53. Jones SE, Jomary C (2002) Clusterin. Int J Biochem Cell Biol 34:427-31
54. Wilson MR, Easterbrook-Smith SB (2000) Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25:95-98 10.1016/S0968-0004(99)01534-0
55. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR (1999) Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274:6875-6881 10.1074/jbc.274.11.6875
56. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608
57. Rouayrenc JF, Boise LH, Thompson CB, Privat A, Patey G (1995) Presence of the long and the short forms of Bcl-X in several human and murine tissues. C R Acad Sci III 318:537-540
58. Minn AJ, Boise LH, Thompson CB (1996) Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J Biol Chem 271:6312-6606
59. Sintich SM, Steinberg J, Kozlowski JM, Lee C, Pruden S, Sayeed S, Sensibar JA (1999) Cytotoxic sensitivity to tumor necrosis factor alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate 39:87-93
60. Miyake H, Hara I, Kamidono S, Gleave ME, Eto H (2003) Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 10:469-3473
61. Wong P, Pineault J, Lakins J, Taillefer D, Leger J, Wang C, Tenniswood M (1993) Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J Biol Chem 268:5021-5031
62. Lakins J, Bennett SA, Chen JH, Arnold JM, Morrissey C, Wong P, O'Sullivan J, Tenniswood M (1998) Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate. J Biol Chem 273:27887-27895
63. Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, Strickland DK, Argraves WS (1995) Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem 270:13070-13075
64. Sensibar JA, Sutkowski DM, Raffo A et al. (1995) Prevention of cell death induced by tumor necrosis factor in alpha LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res 55:2431-2437
65. Miyake H, Hara I, Gleave ME, Eto H (2004) Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 61: 318-323
66. Pins MR, Fiadjoe JE, Korley F, Wong M, Rademaker AW, Jovanovic B, Yoo TK, Kozlowski JM, Raji A, Yang XJ, Lee C (2004) Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: A preliminary report. Prostate Cancer Prostatic Dis 7:243-248
67. July L, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50:179-188 10.1002/ pros.10047
68. Miyake H, Hara I, Kamidono S, Gleave ME (2001) Synergistic chemosensitization and inhibition of tumour growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 7:4245-4252
69. Zellweger T, Miyake H, July L, Akbari M, Kiyama S, Gleave ME (2001) Chemosensitization of a human renal cell cancer model by antisense TRPM-2 oligodeoxynucleotides both in vitro and in vivo. Neoplasia 3:1-8
70. July LV, Beraldi E, So AI, Evans K, English J, Fazli L, Gleave ME (2004) Nucleotide-based therapies targeting clusterin chemosensitizes human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 3:223-232
71. Crooke ST (1993) Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376
72. Saijo Y, Perlaky L, Wang H, Busch H (1994) Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 6:243-249
73. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668-675
74. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia B, Gleave ME (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-o-(2-methoxy) ethyl chemistry. J Pharmacol Exp Ther 298:934-940
75. Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF (2000) Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther 292:468-479
76. Miyake H, Chi K, Gleave ME (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655-1663
77. Trougakso IP, So A, Jansen B, Gleave ME, Gonos ES (2004) Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64:1834-1842
78. Kyprianou N, King ED, Bradbury D, Rhee JG (1997) Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70:341-348
79. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 92:463-469
80. Chi KN, Eisenhauer E, Fazli L, Jones EC, Powers J, Ayers D, Goldenberg SL, Gleave ME (2004) A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2′methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. J Clin Ocol, Proceedings of American Society of Clinical Oncology, 2004
81. Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wacheck V, Gleave ME, Pehamberger H, Jansen B (2005) Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol (in press)